UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 5 | May 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 5 Issue 12
December-2018
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR1812D74


Registration ID:
310906

Page Number

1211-1217

Share This Article


Jetir RMS

Title

Review on Pharmaceutical Products from Actinomycetes

Abstract

The ineffectiveness of existing antibiotics inculcates the search of novel metabolites from specific ecosystems. Microbial ecosystem specially, actinomycetes a fungi like bacteria consist an extensive and diverse species with an unparalleled ability to produce diverse secondary metabolites high frequently studied by researchers. These bacteria have been studied extensively by the pharmaceutical industry and account for a disproportionately large amount of the $25.3 billion annual global sale. According to the data 2007, the contribution of biologically occurring chemicals in drug development. The actinomycetes products have a tremendous success for the past few decades. Universally Actinomycetes are acknowledged as a vital player in the drug discovery process. Actinomycetes are highly significant in drug discovery and development due to its high G+C content. Among the bioactive compounds, nearly 45 percentage produced by actinomycetes, 35 % by fungi and 20 % by unicellular eubacteria. Apart from infectious disease, Actinomycetes are also reported to produce many industrially and medically important enzymes. Acarbose is an oral alpha-glucosidase and alpha-amylase inhibitor for the oral treatment of type II diabetes mellitus is isolated from actinomycetes. Thus actinomycetes are potent secondary metabolite producer and biotechnologically interesting organism need to explore much. By this review, we explore and update our knowledge on the potential of actinomycetes and their bio-discovery potential.

Key Words

Streptomyces, Micromonospora, myeloma, Natamycin, Diabetes

Cite This Article

"Review on Pharmaceutical Products from Actinomycetes", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 12, page no.1211-1217, June-2021, Available :http://www.jetir.org/papers/JETIR1812D74.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"Review on Pharmaceutical Products from Actinomycetes", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 12, page no. pp1211-1217, June-2021, Available at : http://www.jetir.org/papers/JETIR1812D74.pdf

Publication Details

Published Paper ID: JETIR1812D74
Registration ID: 310906
Published In: Volume 5 | Issue 12 | Year December-2018
DOI (Digital Object Identifier):
Page No: 1211-1217
Country: -, -, India .
Area: Engineering
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000402

Print This Page

Current Call For Paper

Jetir RMS